ClinicalTrials.gg
CompletedNCT01576341SENSEUpdated Jun 19, 2017Results posted

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

A Phase 3 interventional study of HX575 epoetin alfa (Sandoz) in Chronic Kidney Disease, sponsored by Sandoz. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-19.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
7th of 25
417 · median 157
Started
2012
with 4 others
Phase 3
10 of 25
none open now
Registered
18th of 25
by date
Lead sponsor
4 of 25
Sandoz

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 7th largest by enrollment, is one of 5 that started in 2012, is one of 10 in phase 3, and was the 18th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Epoetin alfa, ESA, HX575, CKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Adult male and female patients w or w/o dialysis treatment
  • Stable i.v. or s.c. maintenance therapy with an EU-approved ESA treatment or ESA naïve.
  • Adequate iron substitution

Main Exclusion Criteria:

  • History of Pure Red Cell Aplasia (PRCA) or anti-erythropoietin (EPO) antibodies
  • for ESA therapy
  • Serum albumin \< 3.0 g/dL
  • Immunocompromized patients ( treatment, chemotherapy)
  • infection on an active treatment or or (HIV) infection
  • Systemic lupus erythematosus
  • Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial infarction within 6 months
  • History of of any organ system within the last 5 years
  • History of use of any non-EU approved ESA
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    HX575 epoetin alfa (Sandoz)

    Single arm

    Drug: HX575 epoetin alfa (Sandoz)

Interventions

  • Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.

    Also known as: Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®

06

What researchers measure

Primary outcomes

  1. Anti-Erythropoietin (EPO) Antibodies

    The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay

    Time frame: 52 weeks

Secondary outcomes

  1. Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)

    Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)

    Time frame: 52 weeks

07

Results

Posted Jun 19, 2017

Participant flow

Patients, suffering from anemia associated with chronic Kidney Disease (CKD), were treated s.c. with HX575 at least once per week in order to achieve and maintain Hb concentration within the target range of 10.0 to 12.0 g/dL. 417 patients were enrolled.

Participant flow — Overall Study
MilestoneHX575, Safety Population
Started417
Completed324
Not completed93
Withdrew: Withdrawal by subject24
Withdrew: Adverse event10
Withdrew: Death21
Withdrew: Physician decision2
Withdrew: Lost to follow-up2
Withdrew: Kidney transplantation10
Withdrew: Protocol violation12
Withdrew: Other12

Outcome measures

PrimaryAnti-Erythropoietin (EPO) Antibodies

The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Anti-Erythropoietin (EPO) Antibodies
percentage of participantsHX575
Anti-Erythropoietin (EPO) Antibodies1.7 (0.7 to 3.4)
Statistical analysis
  • HX575 · Incidence rate: 0.019Incidence rate is based on duration of treatment period (years)
SecondaryHemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)

Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)

Time frame:
52 weeks
Reported as:
Mean · g/dL
Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)
g/dLHX575 - ESA NaiveHX575 - ESA MaintenanceHX575
Actual Value10.81 ± 1.33610.86 ± 1.06010.83 ± 1.226
Change from Baseline Period1.61 ± 1.6010.22 ± 1.2231.02 ± 1.606

Adverse events

Collected over 4 weeks (screening period) + 52 weeks (treatment period). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HX575, Safety Population25/416 (6%)103/416 (24.8%)121/416 (29.1%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventHX575, Safety Population
Renal failure chronicRenal and urinary disorders20/416
Myocardial infarctionCardiac disorders5/416
PeritonitisInfections and infestations5/416
PneumoniaInfections and infestations5/416
HypertensionVascular disorders5/416
Angina pectorisCardiac disorders3/416
Cerebrovascular accidentNervous system disorders3/416
Acute coronary syndromeCardiac disorders2/416
Acute myocardial infarctionCardiac disorders2/416
Angina unstableCardiac disorders2/416
Most frequent other events
Most frequent other events
EventHX575, Safety Population
HypertensionVascular disorders42/416
Renal failure chronicRenal and urinary disorders39/416
HyperkalaemiaMetabolism and nutrition disorders19/416
NasopharyngitisInfections and infestations13/416
PneumoniaInfections and infestations10/416
DiarrhoeaGastrointestinal disorders9/416
Oedema peripheralGeneral disorders9/416
Urinary tract infectionInfections and infestations9/416

Baseline characteristics

Safety population: The safety population consists of all patients that received at least one dose of study drug

Age, Continuous
Age, Continuous(years)HX575, Safety Population
Mean52.3 ± 15.78
Sex: Female, Male
Sex: Female, Male(Participants)HX575, Safety Population
Female218
Male198
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HX575, Safety Population
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White416
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)HX575, Safety Population
Russian Federation107
Romania40
Turkey33
Ukraine179
Poland47
Italy5
Germany5
Height
Height(cm)HX575, Safety Population
Mean166.9 ± 9.44
Weight
Weight(kg)HX575, Safety Population
Mean70.6 ± 15.92
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)HX575, Safety Population
Mean25.26 ± 5.073
ESA pre-treatment
ESA pre-treatment(participants)HX575, Safety Population
ESA naive250
ESA maintenance166
08

Study locations

50 sites
  • Sandoz Investigative Site
    Duesseldorf, Germany
  • Sandoz Investigative Site
    Homberg, Germany
  • Sandoz Investigative Site
    Nettetal, Germany
  • Sandoz Investigative Site
    Bari, Italy
  • Sandoz Investigative Site
    Czestochowa, Poland
  • Sandoz Investigative Site
    Gdansk, Poland
  • Sandoz Investigative Site
    Gdynia, Poland
  • Sandoz Investigative Site
    Olkusz, Poland
  • Sandoz Investigative Site
    Plock, Poland
  • Sandoz Investigative Site
    Poznan, Poland
  • Sandoz Investigative Site
    Wadowice, Poland
  • Sandoz Investigative Site
    Warzawa, Poland
  • Sandoz Investigative Site
    Bucuresti, Romania
  • Sandoz Investigative Site
    Constanta, Romania
  • Sandoz Investigative Site
    Lasi, Romania
  • Sandoz Investigative Site
    Oradea, Romania
  • Sandoz Investigative Site
    Timisoara, Romania
  • Sandoz Investigative Site
    Chelyabinsk, Russian Federation
  • Sandoz Investigative Site
    Kemerovo, Russian Federation
  • Sandoz Investigative Site
    Kolomna, Russian Federation
  • Sandoz Investigative Site
    Moscow, Russian Federation
  • Sandoz Investigative Site
    Mytischi, Russian Federation
  • Sandoz Investigative Site
    Nizhny Novgorod, Russian Federation
  • Sandoz Investigative Site
    Novosibirsk, Russian Federation
  • Sandoz Investigative Site
    Orenburg, Russian Federation
  • Sandoz Investigative Site
    Petrozavodsk, Russian Federation
  • Sandoz Investigative Site
    Podolsk, Russian Federation
  • Sandoz Investigative Site
    Pyatigorsk, Russian Federation
  • Sandoz Investigative Site
    Ryazan, Russian Federation
  • Sandoz Investigative Site
    Saratov, Russian Federation
  • Sandoz Investigative Site
    Smolensk, Russian Federation
  • Sandoz Investigative Site
    St. Petersburg, Russian Federation
  • Sandoz Investigative Site
    Yaroslavl, Russian Federation
  • Sandoz Investigative Site
    Yekaterinburg, Russian Federation
  • Sandoz Investigative Site
    Adana, Turkey
  • Sandoz Investigative Site
    Ankara, Turkey
  • Sandoz Investigative Site
    Istanbul, Turkey
  • Sandoz Investigative Site
    Chernovtsy, Ukraine
  • Sandoz Investigative Site
    Dnipropetrovsk, Ukraine
  • Sandoz Investigative Site
    Donetsk, Ukraine
  • Sandoz Investigative Site
    Ivano-Frankivsk, Ukraine
  • Sandoz Investigative Site
    Kharkiv, Ukraine
  • Sandoz Investigative Site
    Kyiv, Ukraine
  • Sandoz Investigative Site
    Lugansk, Ukraine
  • Sandoz Investigative Site
    Nikolaev, Ukraine
  • Sandoz Investigative Site
    Poltava, Ukraine
  • Sandoz Investigative Site
    Ternopil, Ukraine
  • Sandoz Investigative Site
    Uzhgorod, Ukraine
  • Sandoz Investigative Site
    Zaporizhya, Ukraine
  • Sandoz Investigative Site
    Zhitomyr, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2012
First posted
Apr 12, 2012
Start
Apr 2012
Primary completionActual
Oct 2014
CompletionActual
Jun 2015
Results first posted
Jun 19, 2017
Last update
Jun 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01576341
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Apr 2012
Primary completion
Oct 2014
Completion
Jun 2015
Results posted
Jun 19, 2017
Last update
Jun 19, 2017

Study contacts

Sandoz Biopharmaceuticals
study chair · Sandoz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion